FMP

FMP

Enter

DCPH - Deciphera Pharm...

photo-url-https://images.financialmodelingprep.com/symbol/DCPH.png

Deciphera Pharmaceuticals, Inc.

DCPH

NASDAQ

Inactive Equity

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

25.59 USD

0.02 (0.07816%)

About

ceo

Mr. Steven L. Hoerter

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NASDAQ

Description

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to ...

CIK

0001654151

ISIN

US24344T1016

CUSIP

24344T101

Address

200 Smith Street

Phone

781 209 6400

Country

US

Employee

355

IPO Date

Sep 28, 2017

DCPH Financial Summary

CIK

0001654151

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

24344T101

ISIN

US24344T1016

Country

US

Price

25.59

Beta

0.18

Volume Avg.

1.86M

Market Cap

2.21B

Shares

-

52-Week

9.9-25.61

DCF

17.21

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-11.58

P/B

-

Website

https://www.deciphera.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest DCPH News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep